Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dolasetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 8/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.88 |
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.65 |
| ▸ | HTR3B | O95264 | 7/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 2/20 | 0.65 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B | P28222 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | HTR1E | P28566 | 1/20 | 0.65 |
| ▸ | HTR1F | P30939 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | HTR5A | P47898 | 1/20 | 0.65 |
| ▸ | HTR6 | P50406 | 1/20 | 0.65 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolasetron SCHEMBL678304 | 1.00 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL4972030 | 1.00 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL41145 | 1.00 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL7328772 | 1.00 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL7328761 | 1.00 | HTR3A (0.88) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL5013150 | 0.99 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL5655022 | 0.99 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL30167868 | 0.99 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1237588 | 0.99 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL5013147 | 0.99 | HTR3A (0.86) | HTR3AKCNH2SLC6A4HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2404 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3615024-B1 | COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION | ALTO NEUROSCIENCE INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| CN-120192349-A | Preparation method and application of NHC-Ru catalyst containing large steric hindrance functional group | 中国科学院成都有机化学有限公司 | 2025-06-24 | — | — | CN | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| CN-118681024-A | Compositions and methods for treating depression | 才思治疗公司 | 2024-09-24 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| WO-2003011204-A2 | DRUG DELIVERY SYSTEMS | CAPRICORN PHARMA, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-6462017-B1 | THYMOSIN A1 IN CONJUNCTION WITH CHEMODRUG; MEDIATES LOSS OF APPETITE, LOSS OF SLEEP, FATIGUE, REDUCTION IN DAILY ACTIVITY, DECLINE IN OVERALL FEELING, DEPRESSION, NAUSEA AND VOMITING SIDE EFFECTS | SCICLONE PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | claimed |
| CN-1355698-A | Compound for medicine for treating function of bronchial contraction | RESPIRATORIUS AB (SE) | 2002-06-26 | — | — | CN | claimed |
| US-20020044962-A1 | Encapsulation products for controlled or extended release | CHERUKURI S RAO (US) | 2002-04-18 | — | — | US | claimed |
| US-20020044960-A1 | Drug delivery systems | CAPRICORN PHARMA, INC. | 2002-04-18 | — | — | US | claimed |
| US-20020006440-A1 | Rapid-melt semi-solid compositions, methods of making same and methods of using same | CAPRICORN PHARMA, INC. | 2002-01-17 | — | — | US | claimed |
| WO-2002002081-A1 | RAPID-MELT SEMI-SOLID COMPOSITIONS, METHODS OF MAKING SAME AND METHODS OF USING SAME | CAPRICORN PHARMA, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2001082949-A2 | METHOD OF REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS | SCICLONE PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| US-5756514-A | Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists | LARIJANI GHASSEM E (US) | 1998-05-26 | — | — | US | claimed |
| EP-0339669-A1 | Process for preparing indole-3-carboxylic acid esters of trans-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-11-02 | — | — | EP | claimed |